Krystal Biotech (KRYS) - Forward Price-to-Revenue Multiple

Krystal Biotech, Inc. (KRYS) management strictly controls biohazardous waste disposal in compliance with environmental standards. Comparing the company's projected P/S on GURU.Markets, we see the result of their efforts: the value is maintained at 16.00. The business possesses high macro-resilience, as the success of gene therapy does not depend on economic cycles. Current cash flows are growing due to initial sales, although revenue stability relies on insurance coverage.

For Krystal Biotech, Inc. (KRYS), which maintains a monopoly status in the treatment of epidermolysis bullosa, this indicator compares current market capitalization with expected future sales volumes. By analyzing the forward price-to-sales ratio, an investor assesses the innovation premium of gene therapy, where a rising multiple signals inflated expectations, while its decline confirms the business's fundamental resilience to market shocks.